Scientific Success at the AAD Annual Meeting 2026 in Denver

The annual meeting of the American Academy of Dermatology – one of the most important and prestigious events in global dermatology – was held from March 27–31, 2026. The AAD Annual Meeting in Denver once again gathered experts, researchers, and leaders in therapeutic innovation from around the world, serving as an international platform for presenting breakthrough clinical research and exchanging knowledge.

The Penta Hospitals Group and the PI-House Clinical Research Centre in Gdańsk were represented by Dr. hab. n. med. Beata Imko-Walczuk, who was the lead author of a scientific poster presented during the event.

The poster presented the results of the study titled: “Efficacy and Safety of Abrocitinib in Patients with Chronic Hand Eczema: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Trial”

This was a randomized, double-blind, multicenter Phase II, placebo-controlled study evaluating the efficacy and safety of abrocitinib in patients with moderate to severe chronic hand eczema (CHE) of various etiologies.

A total of 82 patients were enrolled in the study and randomized to receive abrocitinib at doses of 200 mg, 100 mg, or placebo for 16 weeks.

Key results included:

The presented results provided important data on a potential new therapeutic option for patients with chronic hand eczema – a condition with a significant impact on quality of life and limited treatment options.

The presentation of these results at the AAD forum was a prestigious distinction and confirmation of the high scientific quality of the research projects conducted. The participation of Dr. hab. n. med. Beata Imko-Walczuk as the lead author of the poster highlighted her key role in the performance and analysis of the study, as well as her active contribution to the development of international clinical research projects in dermatology.

This was not only a personal achievement for the Doctor, but also an important accomplishment for the entire Penta Hospitals team. The presence of our expert among the authors demonstrating the results on one of the most important dermatology stages in the world confirmed that our team includes specialists who actively contribute to the development of modern therapies and international standards of care.